Provided by Tiger Fintech (Singapore) Pte. Ltd.

Innoviva

18.46
-0.0800-0.43%
Post-market: 18.460.00000.00%18:36 EDT
Volume:474.99K
Turnover:8.79M
Market Cap:1.16B
PE:-19.35
High:18.72
Open:18.55
Low:18.36
Close:18.54
Loading ...

HC Wainwright Initiates Innoviva at Buy With $40 Price Target

MT Newswires Live
·
14 Jul

Innoviva Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
14 Jul

Innoviva Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
11 Jul

Armata Pharmaceuticals Inc. Conducted Annual Shareholders Meeting

Reuters
·
14 Jun

FDA Grants Priority Review for Innoviva's Zoliflodacin, Aiming to Introduce First New Gonorrhea Antibiotic in Decades by December 2025

Reuters
·
12 Jun

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target Pdufa Date of December 15, 2025

THOMSON REUTERS
·
12 Jun

Innoviva Inc. Announces FDA Acceptance of New Drug Application for Zoliflodacin, Paving Way for New Gonorrhea Treatment

Reuters
·
10 Jun

Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults

THOMSON REUTERS
·
10 Jun

Innoviva Inc. to Participate in Goldman Sachs 46th Annual Global Healthcare Conference 2025

Reuters
·
03 Jun

Innoviva Elects Board Members and Approves Compensation

TIPRANKS
·
22 May

Innoviva Inc. Conducted Annual Stockholders Meeting, Electing Five Board Members

Reuters
·
22 May

BRIEF-ZEVTERA(Ceftobiprole), An Advanced-Generation Cephalosporin Antibiotic Now Commercially Available In The U.S. To Treat Three Types Of Bacterial Infections

Reuters
·
20 May

Zevtera® (Ceftobiprole), an Advanced-Generation Cephalosporin Antibiotic NOW Commercially Available in the U.S. to Treat Three Types of Bacterial Infections

THOMSON REUTERS
·
20 May

Armata Pharmaceuticals Announces Positive Topline Data from Phase 1b/2a diSArm Trial of AP-SA02 for Staphylococcus aureus Bacteremia

Reuters
·
19 May

Armata Pharmaceuticals Reports Q1 2025 Net Loss of $6.5M, Improvement from $25M Loss in 2024; EPS Loss Narrows to $0.18

Reuters
·
15 May

Innoviva Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
08 May

Innoviva Q1 EPS $(0.74) Misses $0.38 Estimate, Sales $88.63M Beat $82.67M Estimate

Benzinga
·
08 May

BRIEF-Innoviva Q1 Royalty Revenue USD 57.807 Million

Reuters
·
08 May

Armata Pharmaceuticals Secures Additional $4.65 Million Non-Dilutive Funding from U.S. Department of Defense to Support Ongoing Clinical Trial of AP-SA02

Reuters
·
01 May

Health Rounds: Appendectomy appears to reduce ulcerative colitis relapses

Reuters
·
16 Apr